MaxCyte announces departure of Chief Scientific Officer Cenk Sumen

MAXCYTE, INC.

Cenk Sumen, Ph.D., ended employment as Chief Scientific Officer on January 23, 2024.
He will receive 9 months of base salary and COBRA continuation under his severance agreement.
Sumen will remain on MaxCyte's Scientific Advisory Board.
Severance benefits are contingent on execution of a release of claims agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cenk Sumen

Chief Scientific Officer

MXCT · MAXCYTE, INC.

Effective: 2024-01-23
Filed: January 26, 2024, 6:59 PM ET

On January 23, 2024, Cenk Sumen, Ph.D.’s employment as Chief Scientific Officer of MaxCyte, Inc. (the “ Company ”), ended.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cenk Sumen departed as Chief Scientific Officer at MAXCYTE, INC..

Action: ended
Role: Chief Scientific Officer

Exact text from the filing

On January 23, 2024, Cenk Sumen, Ph.D.’s employment as Chief Scientific Officer of MaxCyte, Inc. (the “ Company ”), ended.

View on SEC.gov

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-000593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.